New York City-based Icahn School of Medicine at Mount Sinai has developed a machine learning model to estimate disease risk from rare genetic variants using routine clinical data.
The model was trained on more than 1 million EHRs to quantify risk for 10 common diseases, according to an Aug. 28 news release. Researchers applied it to people with rare DNA mutations and generated a 0-to-1 score reflecting how likely an individual is to develop a specific disease, where a score closer to 1 indicates a greater likelihood.
Mount Sinai researchers analyzed more than 1,600 variants and found that some previously labeled “uncertain” were tied to clear disease patterns, while others believed to be high-risk showed little impact in real-world data.
The team said the tool is not meant to replace clinical judgment, but could help guide screening decisions or reduce unnecessary intervention when genetic test results are ambiguous.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
